Company intelligence / Profile preview
myNEO Therapeutics
- Ownership
- Private
- Employees
- ~20
- Development stage
- Preclinical
Overview
myNEO Therapeutics has developed state-of-the-art AI algorithms for antigen prediction and has discovered novel dark genome-derived antigens ("camyotopes"). Its lead mRNA vaccine candidate for colorectal cancer (CAMYO-01) is moving toward clinical development. The company’s approach aims to unlock immunotherapy options for patients who currently do not respond to existing treatments by targeting previously untapped genomic regions. Preclinical validation supports the potential of camyotopes as game-changing targets in oncology[3][6].
- Therapeutic areas
- Oncology
- Modalities
- mRNA-based cancer vaccinesimmunotherapies
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on myNEO Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on myNEO Therapeutics.